Ravi K Grandhi1, Samuel Lee2, Alaa Abd-Elsayed3. 1. Department of Anesthesiology, Maimonides Medical Center, Brooklyn, NY. 2. Department of Anesthesiology, University of Cincinnati, Cincinnati, OH. 3. Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Abstract
BACKGROUND: Some studies have suggested using epidural analgesia after cancer surgery to reduce metastasis. This article examines the relationship between regional anesthesia (RA) and cancer metastasis in an array of cancers. METHODS: We conducted a review of the literature using PubMed and included 67,577 patients across 28 studies in a metaanalysis, evaluating the hazard ratios (HRs) of overall survival, recurrence-free survival, and biochemical recurrence-free survival. RESULTS: We found no benefit to RA as it relates to cancer. The HR was 0.92 for overall survival, 1.06 for recurrence-free survival, and 1.05 for biochemical recurrence-free survival. Despite the overall analysis showing no benefit, we found some benefit when we evaluated only the randomized trials. However, we found no significant benefit of RA when we evaluated the cancers (gastrointestinal, prostate, breast, and ovarian) individually. CONCLUSION: This metaanalysis shows that RA has no overall survival, recurrence-free survival, or biochemical recurrence-free survival benefit. However, some individual studies have shown significant benefit in terms of cancer recurrence. Further, RA reduces the use of opioids, which has led to some secondary benefits. Further studies are needed to establish the benefits of RA as it relates to cancer.
BACKGROUND: Some studies have suggested using epidural analgesia after cancer surgery to reduce metastasis. This article examines the relationship between regional anesthesia (RA) and cancer metastasis in an array of cancers. METHODS: We conducted a review of the literature using PubMed and included 67,577 patients across 28 studies in a metaanalysis, evaluating the hazard ratios (HRs) of overall survival, recurrence-free survival, and biochemical recurrence-free survival. RESULTS: We found no benefit to RA as it relates to cancer. The HR was 0.92 for overall survival, 1.06 for recurrence-free survival, and 1.05 for biochemical recurrence-free survival. Despite the overall analysis showing no benefit, we found some benefit when we evaluated only the randomized trials. However, we found no significant benefit of RA when we evaluated the cancers (gastrointestinal, prostate, breast, and ovarian) individually. CONCLUSION: This metaanalysis shows that RA has no overall survival, recurrence-free survival, or biochemical recurrence-free survival benefit. However, some individual studies have shown significant benefit in terms of cancer recurrence. Further, RA reduces the use of opioids, which has led to some secondary benefits. Further studies are needed to establish the benefits of RA as it relates to cancer.
Authors: Antje Gottschalk; Justin G Ford; Cedric C Regelin; Jing You; Edward J Mascha; Daniel I Sessler; Marcel E Durieux; Edward C Nemergut Journal: Anesthesiology Date: 2010-07 Impact factor: 7.892
Authors: Kenneth S Tseng; Sachin Kulkarni; Elizabeth B Humphreys; H Ballentine Carter; Jacek L Mostwin; Alan W Partin; Misop Han; Christopher L Wu Journal: Reg Anesth Pain Med Date: 2014 Jul-Aug Impact factor: 6.288
Authors: Federico Longhini; Andrea Bruni; Eugenio Garofalo; Rosalba De Sarro; Riccardo Memeo; Paolo Navalesi; Giuseppe Navarra; Girolamo Ranieri; Giuseppe Currò; Michele Ammendola Journal: Cancer Manag Res Date: 2020-02-10 Impact factor: 3.989
Authors: Ana Catarina Matos; Inês Alexandra Marques; Ana Salomé Pires; Ana Valentim; Ana Margarida Abrantes; Maria Filomena Botelho Journal: Int J Mol Sci Date: 2022-02-08 Impact factor: 5.923
Authors: Amber N Edinoff; Olivia C Derise; Aaron J Sheppard; Sumitra Miriyala; Celina G Virgen; Aaron J Kaye; Mohammad Niakan; Elyse M Cornett; Alan D Kaye Journal: Anesth Pain Med Date: 2022-02-22